|
Exudative vitreoretinopathy 1
|
C536382 |
|
|
Eyebrows duplication of, with stretchable skin and syndactyly
|
C536383 |
|
|
FACES syndrome
|
C536384 |
|
|
3,4-dichlorophenylurea
|
C561340 |
|
|
Facial ectodermal dysplasia
|
C536385 |
|
|
C.I. acid yellow 9
|
C561341 |
|
|
Facial paresis, hereditary, congenital
|
C536386 |
|
|
ERW1227B
|
C561342 |
|
|
Facio thoraco genital syndrome
|
C536387 |
|
|
Faciocardiorenal syndrome
|
C536388 |
|
|
Faciomandibular myoclonus, nocturnal
|
C536389 |
|
|
Evans Syndrome
|
C536380 |
|
|
Metabolic Side Effects of Drugs and Substances
|
D065606 |
[Specific effects of drugs and substances on metabolic pathways such as those occurring through the CYTOCHROME P-450 ENZYME SYSTEM. These include effects that often result in DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; and HERB-DRUG INTERACTIONS.
] |
|
methyl 2,2-difluoro-2-(fluorosulfonyl)acetate
|
C575980 |
|
|
Cytochrome P-450 Enzyme Inhibitors
|
D065607 |
[Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES.
] |
|
trimethylsilyl 2,2-difluoro-2-(fluorosulfonyl)acetate
|
C575981 |
|
|
Renal Reabsorption
|
D065608 |
[The reuptake of water, ELECTROLYTES, and other substances by the KIDNEY to the blood supply.
] |
|
docosahexaenoic acid monoacylglyceride
|
C575982 |
|
|
Cytochrome P-450 CYP1A2 Inhibitors
|
D065609 |
[Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP1A2.
] |
|
aminoacylase III, rat
|
C575983 |
|
